Home › Therapeutic areas › Oncology
Oncology (54 companies · 43 conditions)
Conditions
Non-Small Cell Lung Cancer 16 Colorectal Cancer 15 Breast Cancer 12 Pancreatic Cancer 12 Melanoma 9 Acute Myeloid Leukemia 8 Glioblastoma 7 Prostate Cancer 7 Lymphoma 6 Multiple Myeloma 6 Bladder Cancer 5 Head and Neck Cancer 5 Hodgkin Lymphoma 5 Solid Tumors 5 Cutaneous Squamous Cell Carcinoma 4 Endometrial Cancer 4 Hepatocellular Carcinoma 4 Ovarian Cancer 4 Renal Cell Carcinoma 4 Gastric Cancer 3 Acute Lymphoblastic Leukemia 2 Cervical Cancer 2 Cholangiocarcinoma 2 Gastrointestinal Stromal Tumors 2 Myelodysplastic Syndrome 2 Neuroendocrine Tumors 2 Pediatric Solid Tumors 2 Small Cell Lung Cancer 2 T-Cell Lymphoma 2 Waldenstrom Macroglobulinemia 2 Waldenstrom's Macroglobulinemia 2 Acute Leukemia 1 Chronic Lymphocytic Leukemia 1 Diffuse Large B-Cell Lymphoma 1 Lung Cancer 1 Meningioma 1 Merkel Cell Carcinoma 1 Mesothelioma 1 Nasopharyngeal Carcinoma 1 Neurofibromatosis Type 1 1 Osteosarcoma 1 Sarcoma 1 Skin Cancer 1
Companies
| Ticker | Company | Therapeutic areas | In Oncology | Lead stage | Programs |
|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | Oncology | 5 | Phase 2 | 5 |
| ACTU | Actuate Therapeutics | Oncology | 6 | Phase 2 | 7 |
| ADAG | Adagene Inc. | Oncology | 2 | Phase 2 | 9 |
| AKTS | Aktis Oncology, Inc. | Oncology | 7 | Phase 1 | 9 |
| ALDX | Aldeyra Therapeutics, Inc. | DermatologyOncologyOphthalmology Rare | 1 | NDA Submitted | 8 |
| ALLO | Allogene Therapeutics, Inc. | ImmunologyOncology Rare | 7 | Phase 2 | 12 |
| DRTS | Alpha Tau Medical Ltd. | Oncology | 5 | Phase 2 | 5 |
| ANAB | ANAPTYSBIO, INC | DermatologyGI/HepatologyImmunologyOncology Rare | 1 | Approved | 6 |
| RCUS | Arcus Biosciences, Inc. | DermatologyImmunologyOncology | 3 | Phase 3 | 7 |
| ARTV | Artiva Biotherapeutics, Inc. | DermatologyImmunologyOncologyRenal Rare | 5 | Phase 2 | 16 |
| ARVN | ARVINAS, INC. | NeurologyOncology Rare | 7 | Approved | 15 |
| BCTX | BriaCell Therapeutics Corp. | Oncology | 6 | Phase 3 | 8 |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | Oncology | 8 | Phase 1 | 8 |
| CCCC | C4 Therapeutics, Inc. | Oncology | 1 | Phase 2 | 2 |
| CRBU | Caribou Biosciences, Inc. | ImmunologyOncology | 4 | Phase 3 | 4 |
| CLRB | Cellectar Biosciences, Inc. | Oncology | 9 | NDA Submitted | 11 |
| CGON | CG Oncology, Inc. | Oncology | 1 | NDA Submitted | 1 |
| COGT | Cogent Biosciences, Inc. | HematologyOncology Rare | 3 | NDA Submitted | 7 |
| CHRS | Coherus Oncology, Inc. | Oncology | 1 | Approved | 4 |
| CRVS | Corvus Pharmaceuticals, Inc. | DermatologyOncology | 2 | Phase 3 | 4 |
| CBIO | CRESCENT BIOPHARMA, INC. | Oncology | 8 | Phase 1 | 10 |
| CRNX | Crinetics Pharmaceuticals, Inc. | MetabolicOncology Rare | 2 | Approved | 7 |
| CGEM | Cullinan Therapeutics, Inc. | ImmunologyOncology | 3 | NDA Submitted | 7 |
| CYDY | CytoDyn Inc. | Oncology | 2 | Phase 2 | 2 |
| CTMX | CytomX Therapeutics, Inc. | Oncology | 2 | Phase 1 | 3 |
| ERAS | Erasca, Inc. | Oncology | 1 | Phase 1 | 4 |
| EXEL | EXELIXIS, INC. | Oncology | 2 | NDA Submitted | 2 |
| GLSI | Greenwich LifeSciences, Inc. | Oncology | 1 | Phase 3 | 1 |
| IMTX | Immatics N.V. | Oncology | 7 | Phase 2 | 8 |
| IMRX | Immuneering Corp | Oncology | 4 | Phase 3 | 5 |
| IBRX | ImmunityBio, Inc. | Infectious DiseaseOncology | 13 | Approved | 17 |
| INAB | IN8BIO, INC. | ImmunologyOncology | 3 | Phase 2 | 6 |
| JANX | Janux Therapeutics, Inc. | Oncology | 1 | Phase 1 | 3 |
| KURA | Kura Oncology, Inc. | MetabolicOncology | 7 | Phase 1 | 9 |
| MAIA | MAIA Biotechnology, Inc. | Oncology | 4 | Phase 2 | 7 |
| MRKR | Marker Therapeutics, Inc. | Oncology | 4 | Phase 1 | 4 |
| MDNAF | Medicenna Therapeutics Corp. | Oncology | 3 | Phase 2 | 9 |
| GLUE | Monte Rosa Therapeutics, Inc. | CardiovascularDermatologyMetabolicOncology Rare | 1 | Phase 1 | 8 |
| NRIX | Nurix Therapeutics, Inc. | Oncology | 10 | Phase 2 | 13 |
| OMER | OMEROS CORP | HematologyNeurologyOncologyRespiratory Rare | 1 | NDA Submitted | 7 |
| KTTA | Pasithea Therapeutics Corp. | NeurologyOncology | 1 | Phase 1 | 3 |
| CATX | Perspective Therapeutics, Inc. | Oncology | 2 | Phase 1 | 3 |
| PHIO | Phio Pharmaceuticals Corp. | Oncology | 3 | Phase 1 | 4 |
| PMVP | PMV Pharmaceuticals, Inc. | Oncology | 7 | Phase 2 | 7 |
| PCSA | Processa Pharmaceuticals, Inc. | GI/HepatologyOncologyRenal Rare | 2 | Phase 2 | 8 |
| TARA | Protara Therapeutics, Inc. | DermatologyMetabolicOncology Rare | 1 | Phase 3 | 3 |
| REPL | Replimune Group, Inc. | Oncology | 4 | Phase 3 | 4 |
| SANA | Sana Biotechnology, Inc. | MetabolicOncology | 2 | Phase 1 | 5 |
| SLS | SELLAS Life Sciences Group, Inc. | Oncology | 7 | Phase 3 | 8 |
| SMMT | Summit Therapeutics Inc. | Oncology | 3 | Phase 3 | 3 |
| STRO | SUTRO BIOPHARMA, INC. | Oncology | 3 | Phase 1 | 5 |
| TNGX | Tango Therapeutics, Inc. | Oncology | 4 | Phase 1 | 6 |
| VIR | Vir Biotechnology, Inc. | Infectious DiseaseOncology Rare | 8 | Phase 3 | 10 |
| VOR | Vor Biopharma Inc. | ImmunologyNeurologyOncology Rare | 0 | Phase 3 | 4 |
No companies match.